Antimicrobial Resistance in Posttransplant Cases: A Global Crisis Demanding Urgent Action

Sir/Madam, The escalating threat of antimicrobial resistance (AMR) in posttransplant patients represents an important challenge to global health, one that demands immediate and concerted action from the international medical community. In recent times, we have witnessed firsthand the devastating impact of multidrug-resistant organisms on our most vulnerable patients.[1] The posttransplant setting creates a perfect storm for the emergence and spread of resistant pathogens. Immunosuppression, frequent hospitalizations, and repeated antibiotic exposures inevitably select for increasingly resilient microbes. Extended-spectrum β-lactamase producing Enterobacterales, carbapenem-resistant organisms, and vancomycin-resistant enterococci now dominate our hospital ecosystems, leaving clinicians with ever-dwindling therapeutic options.[2] The implications of AMR extend far beyond individual patients, threatening the very foundations of transplant medicine. Transplant recipients can serve as reservoirs and amplifiers of resistant organisms, potentially seeding outbreaks that extend far beyond the transplant unit. The World Health Organization estimates that bacterial AMR was directly responsible for 1.27 million global deaths in 2019, a figure that will undoubtedly rise without decisive intervention.[3] The economic burden of managing these infections strains healthcare systems globally, jeopardizing the sustainability of transplant programs, particularly in the resource-limited settings. In developing nations such as India, the AMR challenge is complicated by high endemicity of multidrug-resistant organisms, over-the-counter antibiotic availability, and limited infection control infrastructure. Moreover, the specter of untreatable infections may deter potential organ donors, further exacerbating the already critical shortage of transplantable organs. To combat this crisis, we urgently need a multifaceted approach that spans clinical practice, research, and policy: 1) Enhanced hospital-wide and healthsystem-wide antimicrobial stewardship programs which can later be replicated to transplant units, tailored to the unique needs of transplant recipients.[4] These must balance the need for effective prophylaxis and treatment with the imperative to minimize the unnecessary antibiotic exposure 2) Investment in the rapid diagnostics to guide targeted therapy and minimize empiric broad-spectrum antibiotic use. Next-generation sequencing and machine learning algorithms hold promise for revolutionizing our approach to infection diagnosis and management 3) Development of novel nonantibiotic approaches, including bacteriophage therapy, microbiome modulation, and immune-based treatments. These strategies may offer new avenues for managing infections in immunocompromised hosts 4) Global surveillance networks to track emerging resistance patterns and guide empiric therapy protocols.[5] Real-time data sharing across institutions and borders is essential for staying ahead of evolving threats 5) Increased funding for the development of new antimicrobials and alternative treatment strategies. The current pipeline of new antibiotics is woefully inadequate to meet the challenge of AMR 6) Implementation of robust infection prevention and control measures in transplant centers worldwide. Simple interventions such as hand hygiene and environmental cleaning remain cornerstone strategies for reducing the spread of AMR 7) Education and training programs for transplant professionals, focusing on optimal antimicrobial use and the principles of stewardship 8) Policy initiatives to incentivize antibiotic development and ensure equitable access to both new and existing antimicrobials globally. As leaders in the field, we have a responsibility not only to our patients but also to global public health. The future of transplantation may hang in the balance because of AMR. By working together across disciplines and borders, we can preserve this life-saving field for the generations to come. The time for action is now. We call upon our colleagues in transplantation, microbiology, public health, and beyond to join us in this critical fight against AMR. Only through collective efforts, we can turn the tide on this global threat and safeguard the future. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.